Medical Nutrition Scholarship 2023
POA Pharma GmbH
Daring to be extraordinary to benefit the health of all generations
Rapilose® OGS
An Oral Glucose Solution containing 75g of water free glucose in a 300ml solution
POA – Daring to be extraordinary for you
POA Pharma GmbH focuses on the distribution, marketing, and commercialisation of proprietary, generic, and rare disease products, bringing German patients selected products and services of POA Pharma Scandinavia AB.
Founded in 2023, we are committed to doing all we can to improve the lives and benefit the health of all generations affected by a variety of diseases.
Current products include Rapilose® OGS, an Oral Glucose Solution containing 75g of anhydrous glucose in a 300ml solution, which is already available in Germany.
POA Pharma network
POA Pharma GmbH benefits from being part of the wider POA Pharma network, providing the resources to help deliver high quality products and services to German patients.
Based in Copenhagen, POA Pharma Scandinavia AB, the parent company of POA Pharma GmbH, works every day to be of value to patients with inborn metabolic diseases (IMDs) and to their caregivers, offering POA products for Phenylketonuria (PKU) as well as for several other IMDs, which are currently available in the UK, Sweden, Norway, Denmark and Finland and the USA.
Galen Limited
POA Pharma is part of Galen Limited, a privately owned company established in 1968, with global headquarters in Craigavon, Northern Ireland, and commercial operations based in the UK, Ireland, the Nordics, Europe, and the USA. With global partners in every continent, we are positioned to distribute products worldwide.
Galen Limited was founded in Northern Ireland by the late Sir Allen McClay (d. 2010), the revered philanthropist and entrepreneur, and has since become the proud founding member of the Almac Group.
With 6600+ employees and 18 facilities globally, the Almac Group is now owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.
Future Developments
In the course of 2023, POA Pharma GmbH will be introducing its first products to benefit patients with metabolic diseases, including PKU, and in conjunction with Galen Limited, will be running the Medical Nutrition Scholarship Award for the European PKU and IMD community for the third consecutive year.
In celebration of the launch in Germany, extra scholarships for two of the German applicants will be made available in the 2023 Medical Nutrition Scholarship Award programme.
Corporate Social Responsibility
The strategy and activities outlined within this report demonstrate our organisation’s current and future commitment to long-term corporate sustainability and positive corporate impact.
Our strategy aims to maximise our efficiencies and promote fair and sustainable business practices, while ensuring we continue to prioritise initiatives with the greatest impact on human health.
Latest News
POA Pharma announces launch of activities in Germany
20 Apr 2023
POA Pharma Scandinavia AB, a speciality pharmaceutical company with expertise across multiple therapeutic areas, has today announced its expansion into Germany as POA Pharma GmbH.
[...]
POA Pharma enters the German market securing exclusive in-licensing rights for Rapilose® Oral Glucose Solution (OGS)
19 Sep 2022
POA Pharma Scandinavia AB, a Galen Limited owned company, has announced its entry into the German market, securing an exclusive in-licensing agreement with Penlan Healthcare [...]
Galen Medical Nutrition Announces Scholarship Award is open for applications
26 Jul 2021
Supporting patients with metabolic disorders accessing further education
Craigavon, U.K. – 27 Jul 2021 - Galen, the privately-owned pharmaceutical sales and marketing company, is pleased [...]